{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:48:10Z","timestamp":1778878090434,"version":"3.51.4"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A simple and rapid high\u2010performance liquid chromatographic method with ultraviolet detection was developed for the quantitative determination of retigabine, known also as ezogabine, in human plasma. The assay uses a simple solid\u2010phase extraction for sample preparation and direct injection of the extract into the chromatograph. Flupirtine is used as an internal standard. Chromatographic separation is achieved on a C<jats:sub>18<\/jats:sub> Chromolith column (Chromolith Performance, 100 \u00d7 4.6\u2009mm i.d.), using as mobile phase water\/acetonitrile\/methanol (72:18:10\u2009v\/v\/v) mixed with 0.1% of 85% phosphoric acid. Isocratic elution is conducted at a flow rate of 1.5\u2009mL min<jats:sup>\u22121<\/jats:sup>. The total duration of a chromatographic run is 7\u2009min. Calibration curves are linear over the 25\u20132000\u2009ng mL<jats:sup>\u22121<\/jats:sup> concentration range, with a limit of quantitation of 25\u2009ng mL<jats:sup>\u22121<\/jats:sup>. Other performance characteristics include high precision (intra\u2010 and inter\u2010day coefficients of variation \u226412.6%) and high accuracy (99.7%\u2013108.7%). The method is suitable for the investigation of concentration\u2013response relationships in patients receiving therapeutic doses of retigabine.<\/jats:p>","DOI":"10.1002\/bmc.4168","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T23:34:50Z","timestamp":1513121690000},"source":"Crossref","is-referenced-by-count":5,"title":["A simple and rapid HPLC\u2010UV method for the determination of retigabine in human plasma"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-4437","authenticated-orcid":false,"given":"Valentina","family":"Franco","sequence":"first","affiliation":[{"name":"Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics University of Pavia  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Baruffi","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics University of Pavia  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Gatti","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics University of Pavia  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marchiselli","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics University of Pavia  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Fattore","sequence":"additional","affiliation":[{"name":"IRCCS Mondino Foundation  Pavia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Canevini","sequence":"additional","affiliation":[{"name":"Epilepsy Center San Paolo Hospital  Milan Italy"},{"name":"Department of Health Sciences Universit\u00e0 degli Studi di Milano  Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Crema","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics University of Pavia  Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Pharmacology Unit, Department of Internal Medicine and Therapeutics University of Pavia  Pavia Italy"},{"name":"IRCCS Mondino Foundation  Pavia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"606","volume-title":"The Treatment of Epilepsy","author":"Baulac M.","year":"2016"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku070"},{"key":"e_1_2_8_4_1","unstructured":"European Medicines Agency(2011).\u2009Committee for Medicinal Products for Human Use: Guideline on Bioanalytical Method Validation. EMA\/CHMP\/EWP. Retrieved fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/11594640-000000000-00000"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.823399"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700222011210"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00272-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000096"},{"key":"e_1_2_8_10_1","unstructured":"New Hartford Family(2017). Retrieved fromhttp:\/\/fox61.com\/2017\/06\/22\/new\u2010hartford\u2010family\u2010desperate\u2010as\u2010pharmaceutical\u2010company\u2010discontinues\u2010drug\/ posted 17 June 2017 (accessed 18 October 2017)."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01249-1"},{"key":"e_1_2_8_12_1","first-page":"20138","volume-title":"Summary of product characteristics","author":"Trobalt","year":"2016"},{"key":"e_1_2_8_13_1","unstructured":"US Food and Drug Administration(2001).\u2009Guidance for Industry: Bioanalytical Method Validation. Retrieved fromhttps:\/\/www.fda.gov\/downloads\/Drugs\/Guidance\/ucm070107.pdf(accessed 26 October 2017)."}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.4168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.4168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:42:21Z","timestamp":1760042541000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.4168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/bmc.4168"],"URL":"https:\/\/doi.org\/10.1002\/bmc.4168","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"article-number":"e4168"}}